PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Seifert, M.* ; Benmebarek, M.R.* ; Briukhovetska, D.* ; Märkl, F.* ; Dörr, J.* ; Cadilha, B.L.* ; Jobst, J.* ; Stock, S.* ; Andreu-Sanz, D.* ; Lorenzini, T.* ; Grünmeier, R.* ; Oner, A.* ; Obeck, H.* ; Majed, L.* ; Dhoqina, D.* ; Feinendegen, M.* ; Gottschlich, A.* ; Zhang, J.* ; Schindler, U.* ; Endres, S.* ; Kobold, S.

Impact of the selective A2AR and A2BR dual antagonist AB928/etrumadenant on CAR T cell function.

Br. J. Cancer 127, 2175-2185 (2022)
Verlagsversion Forschungsdaten DOI PMC
Open Access Hybrid
Creative Commons Lizenzvertrag
BACKGROUND: Chimeric antigen receptor (CAR) T cell therapy has been successfully translated to clinical practice for the treatment of B cell malignancies. The suppressive microenvironment of many malignancies is a bottleneck preventing treatment success of CAR T cells in a broader range of tumours. Among others, the immunosuppressive metabolite adenosine is present in high concentrations within many tumours and dampens anti-tumour function of immune cells and consequently therapeutic response. METHODS: Here, we present the impact of the selective adenosine A2A and A2B receptor antagonist AB928/etrumadenant on CAR T cell cytokine secretion, proliferation, and cytotoxicity. Using phosphorylation-specific flow cytometry, we evaluated the capability of AB928 to shield CAR T cells from adenosine-mediated signalling. The effect of orally administered AB928 on CAR T cells was assessed in a syngeneic mouse model of colon carcinoma. RESULTS: We found that immunosuppressive signalling in CAR T cells in response to adenosine was fully blocked by the small molecule inhibitor. AB928 treatment enhanced CAR T cell cytokine secretion and proliferation, granted efficient cytolysis of tumour cells in vitro and augmented CAR T cell activation in vivo. CONCLUSIONS: Together our results suggest that combination therapy with AB928 represents a promising approach to improve adoptive cell therapy.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Altmetric
9.075
0.000
7
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter Adenosine Receptors; Antigen; Inhibition; Immunotherapy; Activation; Expression; Suppression; Remissions; Metabolism; Generation
Sprache englisch
Veröffentlichungsjahr 2022
HGF-Berichtsjahr 2022
ISSN (print) / ISBN 0007-0920
e-ISSN 1532-1827
Zeitschrift British Journal of Cancer BJC
Quellenangaben Band: 127, Heft: 12, Seiten: 2175-2185 Artikelnummer: , Supplement: ,
Verlag Nature Publishing Group
Verlagsort Campus, 4 Crinan St, London, N1 9xw, England
Begutachtungsstatus Peer reviewed
Institut(e) Unit for Clinical Pharmacology (KKG-EKLiP)
POF Topic(s) 30203 - Molecular Targets and Therapies
Forschungsfeld(er) Immune Response and Infection
PSP-Element(e) G-522100-001
Förderungen Deutsche Forschungsgemeinschaft (German Research Foundation)
DOI 10.1038/s41416-022-02013-z
WOS ID 000870671500001
WOS ID WOS:000870671500001
Scopus ID 85140237648
PubMed ID 36266575
Erfassungsdatum 2022-10-25
[➜Korrektur melden]